Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other financing activities (2020 - 2025)

Historic Other financing activities for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to -$207000.0.

  • Bioventus' Other financing activities fell 837.7% to -$207000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 6721.07%. This contributed to the annual value of $1.2 million for FY2024, which is 6776.84% down from last year.
  • Bioventus' Other financing activities amounted to -$207000.0 in Q3 2025, which was down 837.7% from -$209000.0 recorded in Q2 2025.
  • Bioventus' Other financing activities' 5-year high stood at $4.0 million during Q4 2023, with a 5-year trough of -$209000.0 in Q2 2025.
  • Its 5-year average for Other financing activities is $318157.9, with a median of -$17000.0 in 2021.
  • The largest annual percentage gain for Bioventus' Other financing activities in the last 5 years was 3641818.18% (2023), contrasted with its biggest fall of 98333.33% (2023).
  • Bioventus' Other financing activities (Quarter) stood at $1.9 million in 2021, then plummeted by 100.59% to -$11000.0 in 2022, then skyrocketed by 36418.18% to $4.0 million in 2023, then plummeted by 56.35% to $1.7 million in 2024, then crashed by 111.87% to -$207000.0 in 2025.
  • Its last three reported values are -$207000.0 in Q3 2025, -$209000.0 for Q2 2025, and -$203000.0 during Q1 2025.